SKorea Hopes New Speed Train Links Will Help Boost Birthrate

A woman walks as the skyline is covered with a thick haze caused by yellow dust at a park in Goyang, South Korea, Friday, March 29, 2024. (AP Photo/Ahn Young-joon)
A woman walks as the skyline is covered with a thick haze caused by yellow dust at a park in Goyang, South Korea, Friday, March 29, 2024. (AP Photo/Ahn Young-joon)
TT

SKorea Hopes New Speed Train Links Will Help Boost Birthrate

A woman walks as the skyline is covered with a thick haze caused by yellow dust at a park in Goyang, South Korea, Friday, March 29, 2024. (AP Photo/Ahn Young-joon)
A woman walks as the skyline is covered with a thick haze caused by yellow dust at a park in Goyang, South Korea, Friday, March 29, 2024. (AP Photo/Ahn Young-joon)

South Korea is launching a high-speed train service that will reduce the travel time between central Seoul and its outskirts, a project officials hope will encourage more youth to consider homes outside the city, and start having babies, Reuters reported.
South Korea has the world's lowest fertility rate, and its youth have often cited long commutes and cramped, expensive housing in greater Seoul, home to about half the population, as the main reasons for not getting married and starting a family.
The birth rate in Seoul is even lower than the national average, and the government has tried to boost the number of newborns through subsidies, with little success.
Officials are now pinning their hopes on the Great Train eXpress (GTX), a 134 trillion won ($99.5 billion) underground speedtrain project that, by 2035, will provide six lines linking Seoul to several outlying areas.
On Friday, President Yoon Suk Yeol inaugurated a section of the first line, which will cut the commute time from Suseo in capital to the satellite city of Dongtan to 19 minutes from 80 minutes now on a bus.
The shorter commute "will enable people to spend more time with their family in the mornings and evenings," he added.
The line is due to go into service on Saturday, and once fully operational, the GTX will be one of the fastest underground systems in the world, with trains travelling at speeds of up to 180 km per hour (112 mph), officials said.
Owning a home in South Korea is costly, with median prices hitting a peak in June 2021 after rising 45% over five years. Seoul is particularly expensive, offering some of the worst value for money per square foot of any advanced economy, analysts say.
Land Minister Park Sang-woo told Reuters the GTX would allow young people to consider homes far away from the capital without having to spend hours commuting. The time they get back can go towards their families, he added.
"With two-hour commute on the way home, for example, how can anyone make time for babies? The idea is to give people more leisure time after work," he said.
Some analysts, however, said the GTX could contribute to the decline of rural South Korea, by sucking more people into the already overcrowded capital.
"To revive regional towns facing extinction, the most important thing is to equip other areas with a similar kind of public infrastructure too," said Kim Jin-yoo, professor of Urban Planning & Transportation Engineering at Kyonggi University.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”